<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70884">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182999</url>
  </required_header>
  <id_info>
    <org_study_id>CWI-HVS</org_study_id>
    <nct_id>NCT02182999</nct_id>
  </id_info>
  <brief_title>Continuous Wound Infiltration After Hallux Valgus Surgery</brief_title>
  <acronym>CWI-HVS</acronym>
  <official_title>Continuous Wound Infiltration After Hallux Valgus Surgery A Prospective, Randomized, Double-blind and Placebo-controlled Single-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of continuous wound infiltration with
      ropivacaine in comparison to standard pain management after elective distal metatarsal
      osteotomy for postoperative pain control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average postoperative numeric rating scale (NRS) for pain</measure>
    <time_frame>First 48 postoperative hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>American Orthopaedic Foot and Ankle Society Score (AOFAS)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall satisfaction with surgery</measure>
    <time_frame>6 weeks</time_frame>
    <description>NRS (0 - 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall satisfaction with pain management</measure>
    <time_frame>6 weeks</time_frame>
    <description>NRS (0 - 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak postoperative numeric rating scale (NRS) for pain</measure>
    <time_frame>First 48 postoperative hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hallux Valgus</condition>
  <arm_group>
    <arm_group_label>NaCl 0,9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InfiltraLong-Katheter 19G x 420mm, Pajunk</intervention_name>
    <description>Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.</description>
    <arm_group_label>NaCl 0,9%</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0,9%</intervention_name>
    <description>The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.</description>
    <arm_group_label>NaCl 0,9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>The catheter is connected to the perfusor line filled with ropivacain 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing a distal metatarsal osteotomy (only Chevron or Scarf) and
             lateral release of the adductor halluces muscle with/without concomitant osteotomy of
             the proximal phalanx of the greater toe (Akin) for idiopathic hallux valgus deformity
             will be included.

        Exclusion Criteria:

          -  hallux valgus surgery other then mentioned above or concomitant other procedures

          -  denial to participate and give informed consent

          -  patients with neurological diseases that affect the sensory-motor function

          -  patients with any short-term (1 month) previous surgery on affected lower extremity

          -  allergies or other comorbidity that prohibits standardized pain regime (renal
             insufficiency, severe heart or liver impairment, uncontrolled asthma, history of
             peptic ulcera )

          -  patients unwilling to undergo surgery without general anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer G. Biedermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UK f체r Orthop채die Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer G. Biedermann, MD</last_name>
    <phone>0043 512 504</phone>
    <phone_ext>80315</phone_ext>
    <email>rainer.biedermann@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthias Braito, MD</last_name>
    <phone>0043 512 504</phone>
    <phone_ext>81214</phone_ext>
    <email>matthias.braito@gmail.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UK f체r Orthop채die</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Braito, MD</last_name>
      <phone>0043 512 504</phone>
      <phone_ext>81214</phone_ext>
      <email>matthias.braito@tilak.at</email>
    </contact>
    <investigator>
      <last_name>Rainer G. Biedermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Braito, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dietmar Dammerer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Schlager, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 19, 2016</lastchanged_date>
  <firstreceived_date>June 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Rainer Biedermann, MD</investigator_full_name>
    <investigator_title>MD, PD</investigator_title>
  </responsible_party>
  <keyword>Hallux valgus surgery</keyword>
  <keyword>wound infiltration</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
